

Pharmaceutical Company in Human and Animal Health Markets

Management Team

Steve Tyrrell

Co-Founder & CEO

25 years of startup leadership in healthcare product markets, introducing new ideas and leading diverse teams from the earliest stages to market

Steve Dow D.V.M., Ph.D.

Co-founder & CSO

Professor in the Department of Clinical Sciences at Colorado State University. Dr. Dow is a prolific investigator and has successfully moved discoveries from his labs to market with Zelnote™

Uses

1. Broad Spectrum Anti Respiratory Viral
2. Viral Eye Infections
3. Epithelial Cancers

Financial Information

Company Stage: Pre-Seed

Previous Capital: Friends & Family

Capital Seeking: \$250,000 to validate lead indication

Contact Information

Steve Tyrrell

CEO

steve.tyrrell@laporteimmuno.com

720-206-5868

<https://www.laporteimmuno.com>

What We Do

Laporte Immunotherapeutics offers candidate immunomodulating drugs with better therapeutic utility, efficacy, and dosing profiles to treat viral infections of the eyes and respiratory system.

The technology is a liposomal TLR agonist proven to stimulate key aspects of the immune system. The drug technology under development has shown broad utility. Animal model efficacy has been demonstrated for respiratory antiviral, ocular viral infections, and squamous cell carcinoma of the eye indications.

The leading use is as a nasal spray to prevent respiratory viral infection including SARS-CoV-2, animal studies are underway. Once efficacy is clinically demonstrated and regulatory approvals obtained, our lead respiratory viral indication represents a very large market opportunity encompassing 100s of millions of people worldwide on a yearly basis.

Business Model

Profit Formula – Laporte will spend to build a strong patent portfolio and generate key drug performance data. We will generate revenue through asset sales or technology licensing.

Key Resources – Laporte has scientists with deep subject matter expertise who can leverage University resources and we have engaged top regulatory consultants to develop the path to market.

Our Processes – Marketing and sales will be handled by Company leadership since our customers consist of fewer than 20 large pharma companies and there are well defined channels and processes in place to move deals forward. High level product roadmaps for human and veterinary product lines are in place.

Summary

- Potential revenue for MucosImmune as a respiratory viral (including SARS-CoV-2) immunotherapeutic projects at \$1 to \$5 billion in sales and \$75 to \$435 million a year in royalties.
- Regulatory firm engaged, FDA pre-IND meeting in late 2020 human safety and efficacy data in 2023-2024, Possible acceleration with funding and possible FDA accommodations due to SARS-CoV-2.
- Customers engaged, Animal Health well underway, early interest from human pharma.
- Strong proof-of-concept, CoV-2 *in vitro* efficacy demonstrated.
- 30+ peer reviewed publications describing technology.
- Composition of matter patent issued.